secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2023-04-27T23:59:59+00:00
Accession:  0000950170-23-015303
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Kezar Life Sciences President & CSO Kirk resigns, enters $41K/mo advisor deal
-----------------------------------------------------------------------------

- Christopher Kirk resigned as President and CSO effective April 21, 2023, remains on board.
- Advisor agreement runs April 22 to Dec 31, 2023 at $41,050/month plus COBRA premiums.
- Kirk declines cash and equity compensation under Non-Employee Director Compensation Policy during term.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000095017023015303/0000950170-23-015303-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000095017023015303/kzr-20230421.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-015303

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer